The Fund supports several networks of state health policymakers to help identify, inspire, and inform policy leaders.
The Milbank Memorial Fund supports two state leadership programs for legislative and executive branch state government officials committed to improving population health.
The Fund identifies and shares policy ideas and analysis on topics important to state health policymakers, particularly on issues related to state leadership, primary care, aging, and health care costs.
Keep up with news and updates from the Milbank Memorial Fund. And read the latest blogs from our thought leaders, including Fund President Christopher F. Koller.
The Fund publishes The Milbank Quarterly, as well as reports, issues briefs, and case studies on topics important to health policy leaders.
The Milbank Memorial Fund is is a nonpartisan foundation focused on improving the health of communities and entire populations.
Opinion Public Health
Robert P. Pack
Cheryl G. Healton
Back to The Milbank Quarterly
The historic tobacco Master Settlement Agreement (MSA) between 46 State Attorneys General and the tobacco industry in 1999 had a range of consequences. It resulted in the closure of tobacco industry policy groups that undermined public health, sharply reduced tobacco marketing using cartoon characters (eg, Joe Camel) and paid product placement in television, film and other media, and created a new nonprofit foundation whose primary goal was to educate youth and prevent them from initiating tobacco use. It also resulted in more than $206 billion in resources being allocated to states, subject to appropriation by state legislators and governors. This enabled states to recoup the cost of medical and other treatment expenditures for tobacco‐related illness.1 However, by 2018, only 2.6% of the $206 billion in settlement and tobacco state taxes had been used for tobacco‐related harm mitigation or prevention.2
In 2018, Dr. Robert Redfield, director of the US Centers for Disease Control and Prevention called the current crisis of overdose deaths “the defining epidemic of our time.” The parallels between the opioid crisis and the historic tobacco crisis are striking: both ran rampant for decades before systematic legal and policy efforts to combat them took hold, both relied on addictive agents difficult to quit once tolerance is high, and both were driven by corporations that made billions of dollars from their sale, facilitated by aggressive, sophisticated, and targeted marketing.
There is now the potential for a settlement agreement between the plaintiffs and defendants in the myriad opioid lawsuits that are making their way through the federal court system. More than 2,400 municipalities, counties, and states have sued opioid manufacturers, pharmaceutical distributors, and corporate pharmacy chains for damages resulting from the opioid crisis. In contrast with the tobacco settlement, the primary basis for the opioid lawsuits is to secure damages resulting from the public nuisance created by the defendants and to mitigate the harm, rather than to recoup medical and treatment costs. Hence, Attorneys General and other plaintiffs in these lawsuits have the opportunity to negotiate settlement terms that assure funds will be used for maximum public health benefit relative to the opioid crisis.
Preliminary settlement discussions that have not included all parties total at least $48 billion,3 but experts estimate that the settlement could be in the range of $50‐100 billion.4 This pales in comparison to the actual cost of the nonmedical use of opioids, estimated to have caused at least $631 billion in economic damages in the past four years alone.5
Resources obtained from a potential settlement should be used exclusively for proven public health approaches that directly address the crisis. The key questions to ask at this point are: what should be done (ie, what programs, systems, policies, and infrastructure should be put in place or bolstered); to what extent should each be done; and how should the resources be allocated to execute such a plan?
What Should Be Done?
The epidemic is expected to continue unless there is a large‐scale systematic implementation of evidence‐based programs and policies to combat it. The Association of Schools and Programs of Public Health (ASPPH) has released a report of the Task Force on Public Health Initiatives to Address the Opioid Epidemic, which outlines proven public health strategies to reduce risk for addiction and to mitigate further harm from the crisis.6 The Task Force made recommendations in the areas of substance use disorder prevention, harm reduction, access to medications for opioid use disorder, stigma reduction, advocacy, and changes to industry practices, but was silent on the proportion of total resources to invest in each domain.
In a 2018 New York Times article, 30 experts were polled regarding proportionate investments of a fictional $100 billion to address potential solutions to the opioid crisis.7 The panel recommended that 47% of resources go for treatment (including medications for opioid use disorder, Medicaid expansion, treatment for the incarcerated, and pre‐trial diversion), 27% for demand reduction (including preventive measures such as community development, post‐incarceration support, education, and pain research), 15% for harm reduction (including naloxone, syringe service and surveillance programs, supervised consumption spaces, HIV/hepatitis treatment, and drug checking, such as fentanyl test strips), and 11% for supply reduction (including prescription monitoring, local police, interdiction, and other diversion controls).
Although the results of this modified Delphi‐panel survey might reflect a number of biases, the poll may be a good starting point for conversation about resource allocation that could lead to more rigorous surveys involving a larger number of stakeholders asked a similar question with discrete response categories limited to evidence‐based approaches with proven returns on investment.
How Should the Resources Be Distributed?
We believe that all resources from a potential opioid MSA should be used to address the addiction and overdose crisis and not be allocated to states for redirected appropriation. Attorneys General and judges must work diligently to avoid redirected appropriation for the obvious reason that it would be “penny wise and pound foolish” in light of the extraordinary scope of the opioid epidemic.
We propose a model that builds on public comments made by Pennsylvania Attorney General Josh Shapiro in November 2019, as reported by the Pittsburgh Post‐Gazette3:
To date, the plaintiffs have borne the cost of both the litigation and the crisis, and we recognize that the ideas presented here may be controversial. However, a new national nonprofit with a public sector board, together with increased federal and local support, would supply high‐need communities with fiscal and programmatic resources in a rapid systematic response using proven dissemination, implementation, and social franchising intervention tools to assure institutionalization of the programs and continuous quality improvement of such programs. This would provide, in our opinion, the best possible way to ensure high return on investment of settlement funds to mitigate the opioid epidemic.
Published 2020 DOI: 10.1111/1468-0009.12450
Robert P. Pack is associate dean for academic affairs and professor of community and behavioral health at East Tennessee State University (ETSU) College of Public Health. Pack is executive director of the ETSU Addiction Science Center and co-director of the Opioids Research Consortium of Central Appalachia. He chaired the Association of Schools & Programs of Public Health Task Force on Public Health Initiatives to Address the Opioid Crisis. He holds a PhD in health education and health promotion from the University of Alabama at Birmingham School of Public Health.
Cheryl G. Healton is dean of School of Global Public Health and professor of public health policy and management at New York University. Previously, Healton was the founding President and CEO of Legacy, a leading organization dedicated to tobacco control, where she guided the national youth tobacco prevention counter-marketing campaign, truth®, which has been credited with reducing youth smoking prevalence to near record lows. Healton has published more than 100 peer-reviewed papers and special reports on public health related topics including HIV/AIDS, public health education, health policy, substance abuse, and tobacco. She was the founding chair of the Public Health Practice Council of the Association of Schools of Public Health and is an active member of the public health community, serving on the National Board of Public Health Examiners, the Betty Ford Institute, and Lung Cancer Alliance. She also serves on the Board of Directors at the Association of Schools and Programs of Public Health, and the Board of Directors at HealthRight International.
Sandro Galea, a physician, epidemiologist, and author, is dean and Robert A. Knox Professor at Boston University School of Public Health. He previously held academic and leadership positions at Columbia University, the University of Michigan, and the New York Academy of Medicine. He has published extensively in the peer-reviewed literature, and is a regular contributor to a range of public media, about the social causes of health, mental health, and the consequences of trauma. He has been listed as one of the most widely cited scholars in the social sciences. He is chair of the board of the Association of Schools and Programs of Public Health and past president of the Society for Epidemiologic Research and of the Interdisciplinary Association for Population Health Science. He is an elected member of the National Academy of Medicine. Galea has received several lifetime achievement awards. Galea holds a medical degree from the University of Toronto, graduate degrees from Harvard University and Columbia University, and an honorary doctorate from the University of Glasgow.
Get the Latest from the Milbank Memorial Fund
The Milbank Quarterly’s multidisciplinary approach and commitment to applying the best empirical research to practical policymaking offers in-depth assessments of the social, economic, political, historical, legal, and ethical dimensions of health and health care policy.